trending Market Intelligence /marketintelligence/en/news-insights/trending/vx-u0aUhB_WOw0Om7udzhg2 content esgSubNav
In This List

Novartis/Ophthotech combo therapy fails phase 3 trial

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Novartis/Ophthotech combo therapy fails phase 3 trial

Novartis AG and Ophthotech Corp.'s joint phase 3 clinical trial to treat macular degeneration missed its primary endpoint.

The combination therapy of anti-platelet-derived growth factor drug Fovista with Lucentis, an anti-vascular endothelial growth factor drug, did not achieve its primary endpoint of change in visual acuity at 12 months for the treatment of wet age-related macular degeneration, a cause of vision loss.

Ophthotech entered into a licensing and commercialization agreement with Novartis in May 2014 and granted the pharmaceutical giant exclusive rights to commercialize Fovista outside of the U.S. in a deal involving $330 million in upfront fees and valued at over $1.0 billion at the time.